In Depth 13 Jul 2023 Gold rush over: what happens to biotech now that venture capital is out of reach? If you were to look back just a little over two years ago to the start of 2021, then putting money into a biotech company seemed like a pretty safe bet. After all, the COVID-19 pandemic had shined a positive spotlight on the biopharmaceutical industry, and initial public offerings (IPOs) were booming. But the last […] July 13, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2023 Gene therapy company EG 427 raises €18M EG 427, a French biotechnology company leading the development of pinpoint DNA medicine solutions, has announced the final closing of a Series A financing. The gene therapy company raised an additional €5 million ($5.6 million) in the final closing from a combination of existing investors and new family office investors, bringing the total raised in […] July 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2023 Crossbow Therapeutics launches with $80M to target cancer Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding. The round was led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture […] July 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 NK:IO awarded £1.6M grant to develop NK cell therapy NK:IO, a U.K. company working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, has been awarded £1.6 million ($2.1 million) in grant funding from Innovate UK’s New Cancer Therapeutics program. The funding will support preclinical development, including development of a manufacturing process in collaboration […] July 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 TolerogenixX expands trial and closes €12M financing TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression […] July 7, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 6 Jul 2023 The biggest private biotech investments in June 2023 The companies Upstream Bio, Alkeus Pharmaceuticals and Worg Pharmaceuticals bagged the biggest biotech investments in June 2023, with oncology and ophthalmology players in particular attracting the most funding rounds. Overall, more funding rounds took place in June 2023 than in May, and the U.S. healthcare sector once again attracted particularly big rounds. We’ve gathered the […] July 6, 2023 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2023 £100M LifeArc program aims to help people living with rare diseases LifeArc, a self-funded, non-profit medical research organization and charity, is launching a new program to invest more than £100 million ($127.2 million) by 2030 to deliver new breakthroughs to improve the lives of people living with a rare disease. The Rare Disease Translational Challenge will bring together researchers in rare disease with LifeArc to get […] July 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2023 Camena Bioscience raises $10M for DNA synthesis platform Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its DNA synthesis platform, gSynth. Camena Bioscience is the first company to offer the enzyme-based DNA synthesis […] July 4, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2023 Exeliom Biosciences closes €24M financing for lead candidate Exeliom Biosciences has completed a €24 million ($26 million) Series A to progress the clinical development of its therapeutic pipeline. This includes several clinical trials of EXL01, a novel immunotherapy with applications in cancer and in infectious diseases. This follows on from the initial closing of €7 million ($7.6 million) in 2018, a first extension […] July 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2023 Vesalius Biocapital to invest €95M in life science companies Vesalius Biocapital, a Luxembourg-based life sciences venture capital investor, has announced the first close of its fourth fund, Vesalius Biocapital IV, securing more than €95 million ($103.7 million) of commitments. The fund has attracted investors including the European Investment Fund (EIF). Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life […] June 29, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2023 Astraveus exits stealth to advance cell and gene therapy platform Astraveus SAS has emerged from stealth with the completion of an oversubscribed €16.5 million ($18.1 million) Series Seed financing. The company creates modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing. Astraveus has developed the Lakhesys platform, an end-to-end cell foundry that uses deep process optimization and single-use, microfluidic bioprocessors to deliver […] June 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Anoat raises funds to tackle cystic fibrosis Anoat Therapeutics, a French preclinical stage biotechnology company specialized in cystic fibrosis (CF), has raised €2 million ($2.17 million) in seed funding from AdBio partners. Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. Anoat Therapeutics’ goal is to bring a transformative and mutation-agnostic […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email